B7-H3 CAR T-cell therapy(Stanford University)

N/A

Report date: 2026/05/08 20:02:52

Base Information

Drug NameB7-H3 CAR T-cell therapy(Stanford University)

Drug Alias NameB7-H3CARTB7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART)B7-H3 Chimeric Antigen Receptor T CellsB7-H3CART

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionT lymphocyte replacementsAnti-CD276

TargetsCD276 antigen

Therapy Area/IndicationsNervous System DiseasesOvarian NeoplasmsNeuroblastoma +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesStanford University

China Registration ClassN/A

Develop Information

Active CompaniesStanford University

Inactive CompaniesN/A

Active IndicationsNervous System DiseasesOvarian NeoplasmsNeuroblastoma +[5]

Inactive IndicationsN/A

Other Information

ATC CodeN/A